Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 17/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 17/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.76 |
| ▸ | INSR | P06213 | 1/20 | 0.76 |
| ▸ | LCK | P06239 | 1/20 | 0.76 |
| ▸ | CCR4 | P51679 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1401327 | 1.00 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL1401392 | 0.99 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL1401332 | 0.91 | PDGFRB (0.83) | PDGFRBPDGFRAEGFRINSRLCK | |
| Hydrochloric Acid SCHEMBL1401313 | 0.90 | PDGFRB (0.81) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL7651057 | 0.87 | PDGFRB (0.80) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL12856395 | 0.87 | PDGFRB (0.76) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL1401305 | 0.86 | PDGFRB (0.78) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL842648 | 0.86 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL842647 | 0.86 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK | |
| SCHEMBL3393843 | 0.86 | PDGFRB (1.00) | PDGFRBPDGFRAEGFRINSRLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1001945-B1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2011-03-02 | — | — | EP | claimed |
| CN-101293869-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases | AVENTIS PHARM PROD INC (US) | 2008-10-29 | — | — | CN | claimed |
| CN-100390154-C | Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors | AVENTIS PHARM PROD INC (GB) | 2008-05-28 | — | — | CN | claimed |
| US-20030139399-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. | 2003-07-24 | — | — | US | claimed |
| US-20030139400-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2003-07-24 | — | — | US | claimed |
| US-20030130285-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | AVENTIS PHARMACEUTICALS INC. | 2003-07-10 | — | — | US | claimed |
| CN-1342150-A | Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors | AVENTIS PHARM PROD INC (US) | 2002-03-27 | — | — | CN | claimed |
| EP-1133480-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS | Aventis Pharmaceuticals Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| US-6180632-B1 | USE OF THESE COMPOUNDS FOR TREATING DISORDERS/CONDITIONS INVOLVING CELLULAR DIFFERENTIATION, PROLIFERATION, EXTRACELLULAR MATRIX PRODUCTION OR MEDIATOR RELEASE AND/OR T CELL ACTIVATION AND PROLIFERATION | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2001-01-30 | — | — | US | claimed |
| EP-1001945-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | claimed |
| CN-1261353-A | Inhibition of platelet-derived growth factor and/or p56lckQuinoline and quinoxaline compounds of tyrosine kinases | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | CN | claimed |
| WO-2000031051-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | claimed |
| EP-1001945-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-05-24 | — | — | EP | claimed |
| EP-1001945-B1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | AVENTIS PHARMA INC (US) | 2011-03-02 | — | — | EP | disclosed |
| CN-101293869-A | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p561lck tyrosine kinases | AVENTIS PHARM PROD INC (US) | 2008-10-29 | — | — | CN | disclosed |
| CN-100390154-C | Quinoline and quinoxaline compounds as PDGF-receptor and/or LCK tyrosine kinase inhibitors | AVENTIS PHARM PROD INC (GB) | 2008-05-28 | — | — | CN | disclosed |
| EP-1001945-A4 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES | RHONE POULENC RORER PHARMA (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-2000031051-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS AS PDGF-RECEPTOR AND/OR LCK TYROSINE KINASE INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-1001945-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56?lck TYROSINE KINASES | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1998054158-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139400-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and /or p56lck tyrosine kinases | LCK, LTK, PTK6 | PDGFRB 27/4885PDGFRA 32/4885EGFR 1365/4885 |
| US-20030130285-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | PDGFRB 27/4885PDGFRA 32/4885EGFR 1365/4885 |
| US-20030139399-A1 | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | LCK, LTK, PTK6 | PDGFRB 27/4885PDGFRA 32/4885EGFR 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.